|Abstract:||A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.|
|Inventor(s):||S.o slashed.rensen; Hans Holmegaard (Virum, DK), Skriver; Lars (Ved.ae butted.k, DK), Hoelgaard; Annie Rassing (Holte, DK)|
|Assignee:||Novo Nordisk A/S (Bagsvaerd, DK)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Formulation; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||1197222||► subscribe|
|European Patent Office||0618807||► subscribe||SPC008/2003||Ireland||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.